Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Amdocs Partners VodafoneZiggo, Ups The Ante In NFV Market

Published 10/13/2019, 10:10 PM
Updated 07/09/2023, 06:31 AM

Amdocs (NASDAQ:DOX) recently entered into a NFV (Network Function Virtualization) partnership with Dutch communication and entertainment provider VodafoneZiggo.

Reportedly, Amdocs will provide NFV solution to help VodafoneZiggo’s enterprise customers design, deploy and monitor virtual cloud networks on-demand.

As part of the project, Amdocs will aid VodafoneZiggo’s strategy to drive network virtualization and service innovation across its infrastructure. The partnership will require VodafoneZiggo to move to a single virtual capability located in its NFV cloud data center, and reduce network total cost of ownership.

Amdocs will add a new network and service orchestration and automation layer by delivering its NFV Orchestrator and Generic Virtual Network Function Manager to automate every aspect of VodafoneZiggo’s service lifecycle management.

Notably, VodafoneZiggo is a key driver of digitization within the European Union with a large customer base in the Netherlands. This partnership is therefore expected to benefit Amdocs by increasing its reach to VodafoneZiggo’s wide network of enterprise customers.

NFV: A Key Growth Driver

Amdocs’ NFV area is witnessing positive developments, which is aiding the company’s growth.

In September 2019, Amdocs and Samsung (KS:005930) partnered to jointly deliver services including NFV solutions. This allowed Amdocs to combine its expertise in enterprise-grade ONAP with Samsung’s advanced 5G network solutions portfolio to help CSPs speed up the development of new services.

Moreover, last year, Amdocs signed a deal with Comcast (NASDAQ:CMCSA) on the latter’s SD-WAN offering, which leveraged the leading energy portfolio of the former, bringing orchestration, fulfilment and automation capabilities to service providers.

In an effort to strengthen its presence in the 5G and NFV spaces, Amdocs also announced the acquisition of TTS Wireless in August this year to strengthen capabilities in open cloud and 5G network.

Per a Technology Business Research report, investments in telecom service provider NFV and software defined networking are expected to exceed $168 billion by 2022.

The number of global service providers, which are evaluating NFV, are also on the rise. Amdocs’ constant efforts to enhance capabilities in this front are likely to help it cash in on this opportunity.

Notably, in the last reported quarter, strong growth in Amdocs’ managed services business was driven by the continued ramp-up of managed transformation activities for customers like PLDT (NYSE:PHI) and Infineon (OTC:IFNNY) . It is combining the deployment of large-scale data transformation projects with operational benefits of its managed services model.

Rising Competition: A Concern

Companies operating in the NFV market are following product development strategies to meet the need of customers.

Some of the key players competing with Amdocs in the NFV market are Huawei, Broadcom (NASDAQ:AVGO), Ericsson (BS:ERICAs), Juniper, AT&T (NYSE:T), Nokia (HE:NOKIA) and F5 Networks (NASDAQ:FFIV).

For instance, AT&T is on track to virtualize 75% of its core network operations by 2020, leveraging the ONAP.

Moreover, in February this year, F5 Networks added carrier-grade network address translation as a stand-alone package to its NFV portfolio.

Nonetheless, Amdocs’ constant efforts to enhance capabilities in this front are expected to help it strengthen foothold in the NFV market.

The company currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Amdocs Limited (DOX): Free Stock Analysis Report

Comcast Corporation (CMCSA): Free Stock Analysis Report

Infineon Technologies AG (IFNNY): Free Stock Analysis Report

PLDT Inc. (PHI): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.